Aortic valve bioprosthesis Colibri

porcine tissuesutureless

Colibri recently initiated a clinical early feasibility study (EFS) which is an international prospective, non-randomized, single arm, open label, trial to assess early feasibility of the Colibri second-generation 24mm and 27mm percutaneous, ready-for-use, balloon expandable aortic heart valve and delivery system. The company’s second-generation TAVI system includes enhancements to address a wider range of patient candidates including those with bicuspid aortic valves and younger patients that need a more durable valve.